CX Institutional’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $42.6M | Buy |
35,493
+1,675
| +5% | +$1.71M | 1.23% | 17 |
|
|
2026
Q1 | $31.1M | Buy |
33,818
+4,543
| +16% | +$4.61M | 0.95% | 22 |
|
|
2025
Q4 | $31.5M | Sell |
29,275
-1,633
| -5% | -$1.56M | 0.94% | 26 |
|
|
2025
Q3 | $23.6M | Buy |
30,908
+2,191
| +8% | +$1.63M | 0.72% | 32 |
|
|
2025
Q2 | $22.4M | Buy |
28,717
+1,494
| +5% | +$1.16M | 0.78% | 29 |
|
|
2025
Q1 | $22.5M | Buy |
27,223
+3,600
| +15% | +$3M | 0.85% | 27 |
|
|
2024
Q4 | $18.2M | Buy |
23,623
+4,452
| +23% | +$3.69M | 0.72% | 33 |
|
|
2024
Q3 | $17M | Sell |
19,171
-408
| -2% | -$367K | 0.75% | 30 |
|
|
2024
Q2 | $17.7M | Sell |
19,579
-944
| -5% | -$755K | 0.83% | 30 |
|
|
2024
Q1 | $16M | Buy |
20,523
+1,429
| +7% | +$1.02M | 0.77% | 33 |
|
|
2023
Q4 | $11.1M | Sell |
19,094
-2,903
| -13% | -$1.69M | 0.6% | 46 |
|
|
2023
Q3 | $11.8M | Sell |
21,997
-8,330
| -27% | -$4.29M | 0.65% | 46 |
|
|
2023
Q2 | $14.2M | Buy |
30,327
+50
| +0.2% | +$21K | 0.74% | 29 |
|
|
2023
Q1 | $10.6M | Buy |
30,277
+14,029
| +86% | +$4.73M | 0.56% | 42 |
|
|
2022
Q4 | $5.94M | Buy |
16,248
+10,183
| +168% | +$3.61M | 0.36% | 67 |
|
|
2022
Q3 | $1.96M | Buy |
6,065
+705
| +13% | +$223K | 0.14% | 185 |
|
|
2022
Q2 | $1.74M | Buy |
5,360
+625
| +13% | +$188K | 0.13% | 187 |
|
|
2022
Q1 | $1.36M | Buy |
4,735
+412
| +10% | +$106K | 0.11% | 194 |
|
|
2021
Q4 | $1.19M | Buy |
4,323
+88
| +2% | +$22.3K | 0.09% | 187 |
|
|
2021
Q3 | $979K | Sell |
4,235
-42
| -1% | -$10.4K | 0.08% | 215 |
|
|
2021
Q2 | $982K | Sell |
4,277
-9,808
| -70% | -$1.97M | 0.08% | 201 |
|
|
2021
Q1 | $2.63M | Buy |
14,085
+3,351
| +31% | +$655K | 0.24% | 105 |
|
|
2020
Q4 | $1.81M | Sell |
10,734
-1,027
| -9% | -$153K | 0.17% | 163 |
|
|
2020
Q3 | $1.74M | Buy |
11,761
+582
| +5% | +$90.1K | 0.19% | 146 |
|
|
2020
Q2 | $1.83M | Buy |
11,179
+260
| +2% | +$39.9K | 0.24% | 115 |
|
|
2020
Q1 | $1.51M | Buy |
10,919
+8,293
| +316% | +$1.14M | 0.25% | 88 |
|
|
2019
Q4 | $345K | Sell |
2,626
-41
| -2% | -$4.75K | 0.06% | 169 |
|
|
2019
Q3 | $298K | Sell |
2,667
-1,318
| -33% | -$147K | 0.05% | 195 |
|
|
2019
Q2 | $441K | Buy |
3,985
+427
| +12% | +$50.3K | 0.07% | 168 |
|
|
2019
Q1 | $462K | Buy |
3,558
+1,114
| +46% | +$135K | 0.08% | 161 |
|
|
2018
Q4 | $283K | Buy |
+2,444
| New | +$273K | 0.06% | 151 |
|
Other funds holding LLY
CX Institutional's LLY Position: Q2 2026 in Review
CX Institutional increased its Eli Lilly (LLY) stake by 5% in Q2 2026, buying an estimated $1.71M and bringing the position to 35,493 shares worth $42.6M. The position accounts for 1.23% of the portfolio, ranked #17.
CX Institutional first reported a position in LLY in Q4 2018 and has held it in 31 quarters since. 4,624 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- CX Institutional held 35,493 shares of Eli Lilly worth $42.6M as of Q2 2026.
- CX Institutional bought 1,675 Eli Lilly shares in Q2 2026, an estimated $1.71M.
- Eli Lilly made up 1.23% of CX Institutional's portfolio in Q2 2026, its #17 holding.
- CX Institutional first reported a position in Eli Lilly in Q4 2018 and has held it in 31 quarters since.
- 4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on CX Institutional's 13F filing for Q2 2026, filed 2 Jul 2026.